Table 2. Clinical outcome of SCT... | American Society of Hematology

Table 2.

Clinical outcome of SCT stratified by recipient CMV serology

No. of patients	CMV seronegative (n = 9)	CMV seropositive (n = 18)
CMV antigenemia	0	14
Recurrent antigenemia^*	0	7
CMV disease	0	4
Survival status (alive/dead)	7/2	13/5
Cause of death
Relapse of original disease	1	0
CMV disease (main cause)	0	2^†
CMV disease (contributing)	0	1^‡
Chronic GVHD	1	2

No. of patients	CMV seronegative (n = 9)	CMV seropositive (n = 18)
CMV antigenemia	0	14
Recurrent antigenemia^*	0	7
CMV disease	0	4
Survival status (alive/dead)	7/2	13/5
Cause of death
Relapse of original disease	1	0
CMV disease (main cause)	0	2^†
CMV disease (contributing)	0	1^‡
Chronic GVHD	1	2

SCT, stem cell transplant; CMV, cytomegalovirus; GVHD, graft-versus-host disease.

Requiring therapy with ganciclovir.

Death from CMV encephalitis (n = 1) or CMV pneumonitis (n = 1).

Organ affected: bone marrow.